scholarly journals Determination of Plasma Levels of the Active Thiol Form of the Direct-Acting PrC-210 ROS-Scavenger Using a Fluorescence-Based Assay

2021 ◽  
pp. 114100
Author(s):  
Emma Dreischmeier ◽  
William E. Fahl
Keyword(s):  
Plasma Levels ◽  
Ros Scavenger ◽  
Thiol Form ◽  
Direct Acting

Identification of N-Monoacetylcystine in Uraemic Plasma

1981 ◽  
Vol 60 (3) ◽  
pp. 331-334 ◽  
Author(s):  
F. Gejyo ◽  
G. Ito ◽  
Y. Kinoshita
Keyword(s):  
Plasma Levels ◽  
Gel Filtration ◽  
Normal Subjects ◽  
Exchange Chromatography ◽  
Cysteic Acid ◽  
Homocysteic Acid ◽  
Normal Limits ◽  
Acidic Nature ◽  
Sulphur Amino Acids

1. An unidentified ninhydrin-positive substance of an acidic nature was detected in the plasma of uraemic patients. This substance was isolated from haemodialysate by ion-exchange chromatography and gel filtration, and identified as a sulphur-containing amino acid: N-monoacetylcystine. 2. The quantitative determination of sulphur amino acids in plasma revealed that the plasma levels of cysteic acid, homocysteic acid, taurine, cystine and cystathionine as well as N-monoacetylcystine in uraemic patients were markedly higher than in normal subjects (P < 0.001 for each). However, the plasma levels of methionine in uraemic patients were within normal limits.

Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4A Protease Inhibitors in Iranian HCV/HIV Infected Patients

2021 ◽  
Vol 19 ◽  
Author(s):  
Kazem Baesi ◽  
Ali Akbar Velayati ◽  
Masoumeh Farrokh Ashtiani ◽  
Kamal Fakhredini ◽  
Mohammad Banifazl ◽  
...  
Keyword(s):  
Protease Inhibitors ◽  
Standard Treatment ◽  
Large Population ◽  
Host Immune Responses ◽  
Naturally Occurring ◽  
Immunodeficiency Virus ◽  
Direct Acting ◽  
Therapy Success ◽  
Cure Rates

Background: Hepatitis C virus (HCV) acts in host as a complicated mixture of related variants with the potency to genetically escape host immune responses. Direct acting antivirals (DAAs) have been approved for HCV treatment with shorter duration, better cure rates and lower side effects. However, naturally occurring resistance associated substitutions(RASs) make some obstacles to this antiviral therapy success. Objective: In this study, we aimed at determination of the naturally occurring NS3/4A RASs in HCV/human immunodeficiency virus (HIV)infected patients. Methods: A total of 120 DAA-naïve HCV-HIV co-infected patients were included. HCV NS3/4Agenome region was amplified with PCR and mutation analysis was performed by Sanger sequencing technique. The amino acid sequence diversity of the region wasanalyzed using geno2pheno HCV. Results: Phylogenetic analysis showed that 73 cases were infected by 3a and 47 subjects by subtype1a. The overall RASs among studied subjects wereobserved in 6 (5%) individuals from 120 studied cases who were infected with HCV 1a. V36M/L,Q80L,S122G/L,R155T/G,A156S,D168Y/N and S174A/N/T mutations were detected in this study. Conclusion: Although the prevalence of RASs was totally low in this study, the presence of several cases of double and triple mutants among this population suggests prior evaluation of protease inhibitors related mutations before initiation of standard treatment and also investigation on a large population could be of high value.

The Determination of Urinary Oxypurines as Markers of Gastrointestinal Tumors

1987 ◽  
Vol 73 (3) ◽  
pp. 289-294 ◽  
Author(s):  
Marco Lorenzi ◽  
Daniela Vannoni ◽  
Roberto Leoncini ◽  
Ranieri Caldarone ◽  
Enrico Marinello
Keyword(s):  
High Pressure ◽  
Liquid Chromatography ◽  
Urinary Excretion ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Plasma Levels ◽  
Colorectal Tumor ◽  
Reverse Phase ◽  
Tumor Bearing

Plasma levels and urinary excretion of oxypurines – hypoxanthine and xanthine – were evaluated by reverse-phase high-pressure liquid chromatography in 13 patients affected by gastric tumors and in 19 colorectal tumor-bearing patients. Preliminary results indicate higher values of urinary xanthine and an increase in the xanthine/hypoxanthine ratio in cancer patients. The increase was not generalized to all subjects, and did not appear related either to the stage of the disease or to CEA values. The limits within which the determination of urinary oxypurines can be employed as a tumor marker are discussed.

Gene-environment interaction in the determination of plasma levels of fibrinogen

1997 ◽  
Vol 11 ◽  
pp. 3-7 ◽  
Author(s):  
S.E. Humphries ◽  
A. Thomas ◽  
H.E. Montgomery ◽  
F. Green ◽  
A. Winder ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Environment Interaction ◽  
Gene Environment Interaction ◽  
Gene Environment

Use of GC/MS/SIM for rapid determination of plasma levels of o, p′-DDD, o, p′-DDE and o, p′-DDA

1987 ◽  
Vol 170 (2-3) ◽  
pp. 305-314 ◽  
Author(s):  
Masayuki Inouye ◽  
Takaya Mio ◽  
Kimiaki Sumino
Keyword(s):  
Plasma Levels ◽  
Rapid Determination

Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018

2021 ◽  
Author(s):  
Laurent Cotte ◽  
Laurent Hocqueloux ◽  
Maeva Lefebvre ◽  
Pierre Pradat ◽  
Firouze Bani-Sadr ◽  
...  
Keyword(s):  
Antiviral Agents ◽  
Full Cohort ◽  
Direct Acting Antiviral ◽  
Treatment Uptake ◽  
Hcv Prevalence ◽  
Hcv Transmission ◽  
Major Shift ◽  
Hcv Coinfection ◽  
Direct Acting

Abstract Background The arrival of highly effective, well tolerated direct-acting antiviral agents (DAA) led to a dramatic decrease in HCV prevalence. HIV-HCV coinfected patients are deemed a priority population for HCV elimination, while a rise of recently acquired HCV infections in MSM has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort. Methods Retrospective analysis of a prospective HIV-infected cohort from 2012 to 2018. Determination of HCV prevalence, incidence, proportion of viremic patients, treatment uptake and mortality rate in the full cohort and by HIV risk factors. Results From 2012 to 2018, 50861 HIV-infected patients with a known HCV status were followed-up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100PY to 1.25/100PY in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in IVDU (35.6%). In MSM, treatment at acute phase represented 30.0% of treatments in 2018. Conclusions A major shift in HCV epidemiology was observed in HIV-infected patients in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM.

scholarly journals Treatment of Postanoxic Intention Myoclonus with Valproic Acid

1979 ◽  
Vol 6 (1) ◽  
pp. 39-42 ◽  
Author(s):  
J. Bruni ◽  
L.J. Willmore ◽  
B.J. Wilder
Keyword(s):  
Valproic Acid ◽  
Side Effects ◽  
Plasma Levels ◽  
Marked Improvement ◽  
Hepatic Function ◽  
Function Tests ◽  
Therapeutic Doses

SummaryValproic acid in therapeutic doses was used in the treatment of postanoxic intention myoclonus. Disappearance of the myoclonus occurred with marked improvement in the electroencephalogram. No significant side effects were noted. Hepatic function tests were monitored. Determination of valproic acid plasma levels was used to guide therapy. Levels above 55 ßg were generally required. The patient remains free of myoclonus after four and one half months.

Sign in / Sign up

Export Citation Format

Share Document